Indinavir is a protease inhibitor used to treat HIV infection. A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.
- Mechanism
- Curator reviewed
Indinavir inhibits the HIV viral protease enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
- Primary indication
- Indinavir is an antiretroviral drug for the treatment of HIV infection.Curator reviewed · 1 structured indication
- Formula / weight
- C36H47N5O4 · 613.7895 g/mol (avg)
- First approval
- Canada, 2005 · United States, 1996
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
CBVCZFGXHXORBI-PXQQMZJSSA-NSMILESCC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12Targets
What you can answer from here — as of September 21, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
8TransportersSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Indinavir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account